Published in Am J Pathol on June 01, 1999
Gender-based reciprocal expression of transforming growth factor-beta1 and the inducible nitric oxide synthase in a rat model of cyclophosphamide-induced cystitis. J Inflamm (Lond) (2009) 0.92
Role of activins in embryo implantation and diagnosis of ectopic pregnancy: a review. Reprod Biol Endocrinol (2014) 0.76
Evaluation of the interaction between TGF beta and nitric oxide in the mechanisms of progression of colon carcinoma. Clin Exp Metastasis (2005) 0.76
Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem (1982) 27.26
Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol (1988) 14.21
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 13.15
Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science (1987) 8.98
Smad3 mutant mice develop metastatic colorectal cancer. Cell (1998) 3.92
Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell (1993) 3.57
Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J Exp Med (1993) 3.06
Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science (1993) 2.35
TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Immunity (1996) 1.81
Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother (1997) 1.64
Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst (1997) 1.55
The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev (1995) 1.51
High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology (1996) 1.41
Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br J Cancer (1994) 1.39
Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci U S A (1994) 1.21
Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res (1991) 1.20
Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse. J Exp Med (1996) 1.19
Selection by trypsin of two sublines of rat colon cancer cells forming progressive or regressive tumors. Int J Cancer (1983) 1.17
Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol (1994) 1.17
Nitric oxide involvement in tumor-induced immunosuppression. J Immunol (1994) 1.15
Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J Leukoc Biol (1996) 1.09
Intracellular demonstration of active TGFbeta1 in B cells and plasma cells of autoimmune mice. IgG-bound TGFbeta1 suppresses neutrophil function and host defense against Staphylococcus aureus infection. J Clin Invest (1996) 1.08
Direct evidence for an intracellular role for IFN-gamma. Microinjection of human IFN-gamma induces Ia expression on murine macrophages. J Immunol (1990) 1.08
Analysis of endogenous and exogenous nuclear translocation of fibroblast growth factor-1 in NIH 3T3 cells. Biochem Biophys Res Commun (1992) 1.05
Transcriptional inhibition of the inducible nitric oxide synthase gene by competitive binding of NF-kappa B/Rel proteins. Biochem Biophys Res Commun (1995) 1.02
Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes (1997) 1.01
Transforming growth factor beta differentially modulates the inducible nitric oxide synthase gene in distinct cell types. Biochem Biophys Res Commun (1993) 0.98
The role of transforming growth factor beta 1 in the fibroblastic reaction associated with rat colorectal tumor development. Cancer Res (1994) 0.95
Cytokine-receptor complexes as chaperones for nuclear translocation of signal transducers. Biochem Biophys Res Commun (1998) 0.90
Effects of TGF-beta 1 (transforming growth factor-beta 1) on the cell cycle regulation of human breast adenocarcinoma (MCF-7) cells. FEBS Lett (1995) 0.86
Dexamethasone selectively regulates the activity of enzymatic markers of cerebral endothelial cell lines. In Vitro Cell Dev Biol (1992) 0.85
Selective immunosuppressive action of a factor produced by colon cancer cells. Cancer Res (1990) 0.84
Possible involvement of TGF beta 1 in the distinct tumorigenic properties of two rat colon carcinoma clones. Invasion Metastasis (1992) 0.82
Transforming growth factor beta 1 and gamma interferon provide opposing signals to lipopolysaccharide-activated mouse macrophages. Infect Immun (1994) 0.81
Role of transforming growth factor beta in colorectal cancer. Growth Factors (1993) 0.81
Expression of inducible nitric oxide synthase in tumors in relation with their regression induced by lipid A in rats. Int J Cancer (1999) 0.80
Polyclonal antibody against an inducible form of nitric oxide synthase purified from the liver of rats treated with Propionibacterium acnes and lipopolysaccharide. Biochem Biophys Res Commun (1992) 0.80
Nuclear internalisation and DNA binding activities of interleukin-1, interleukin-1 receptor and interleukin-1/receptor complexes. Biochem Biophys Res Commun (1992) 0.79
Control of nitric oxide production by endogenous TGF-beta1 and systemic nitric oxide in retinal pigment epithelial cells and peritoneal macrophages. J Leukoc Biol (1996) 0.78
Immunomodulator OM 163-induced reversal of tumor-mediated immunosuppression and downregulation of TGF-beta 1 in vivo. J Pharmacol Exp Ther (1996) 0.77
Differential-effects of transforming growth-factor-Beta-1 on protein-levels of p21 waf and cdk-2 and on cdk-2 kinase-activity in human rd and ccl64 mink lung-cells. Int J Oncol (1995) 0.77
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A (1998) 3.73
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Immunoglobulins cytophilic for human lymphocytes, monocytes, and neutrophils. J Clin Invest (1975) 3.39
The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature (1996) 3.34
Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res (2000) 3.06
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol (1984) 2.76
Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem Biophys Res Commun (1985) 2.75
Regulation of methionine synthesis in Salmonella typhimurium: mutants resistant to inhibition by analogues of methionine. Genetics (1968) 2.62
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem (2001) 2.40
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem (1984) 2.22
Strand-selective repair of DNA damage in the yeast GAL7 gene requires RNA polymerase II. J Biol Chem (1992) 1.94
Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood (2000) 1.90
Beta-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex. Biochem Biophys Res Commun (1986) 1.90
Familial dementia caused by polymerization of mutant neuroserpin. Nature (1999) 1.88
Further study of beta-TGFs released by virally transformed and non-transformed cells. Int J Cancer (1985) 1.77
Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J (1995) 1.73
Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Anal Biochem (1984) 1.59
Preferential repair of DNA damage on the transcribed strand of the human metallothionein genes requires RNA polymerase II. Mutat Res (1991) 1.58
Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem (2001) 1.58
Latent beta-transforming growth factor in nontransformed and Kirsten sarcoma virus-transformed normal rat kidney cells, clone 49F. Cancer Res (1984) 1.51
The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost (2011) 1.51
Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum (1990) 1.50
Retention and attrition during the preparation phase and after start of antiretroviral treatment in Thyolo, Malawi, and Kibera, Kenya: implications for programmes? Trans R Soc Trop Med Hyg (2011) 1.50
Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem (1997) 1.47
Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A (1998) 1.47
Every-other-week methotrexate in patients with rheumatoid arthritis. A double-blind, placebo-controlled prospective study. Arthritis Rheum (1995) 1.44
Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J Biol Chem (1998) 1.42
Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem (2000) 1.40
The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure (1999) 1.40
Cytophilic properties of IgA to human neutrophils. Adv Exp Med Biol (1974) 1.38
Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. J Immunol (1989) 1.38
The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res (1994) 1.36
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol (2005) 1.33
Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology (2003) 1.23
Characterization of an IgE receptor isolated from cultured B-type lymphoblastoid cells. J Immunol (1978) 1.23
Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur J Immunol (1995) 1.23
Malignant extraovarian endometriosis: a review. Eur J Surg Oncol (2005) 1.23
Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost (2006) 1.21
Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol (2007) 1.20
Lead differentially modifies cytokine production in vitro and in vivo. Toxicol Appl Pharmacol (1996) 1.17
Selection by trypsin of two sublines of rat colon cancer cells forming progressive or regressive tumors. Int J Cancer (1983) 1.17
A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J Biol Chem (1995) 1.16
Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol (1999) 1.16
Nitric oxide involvement in tumor-induced immunosuppression. J Immunol (1994) 1.15
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer (2011) 1.14
Regulation of the methionine-specific aspartokinase and homoserine dehydrogenase of Salmonella typhimurium. J Gen Microbiol (1968) 1.13
The role of fibroblasts in tumor behavior. Cancer Metastasis Rev (1995) 1.10
CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français d'Etude des Lymphomes Cutanés (GFELC). Am J Surg Pathol (1999) 1.10
Neuroserpin mutation S52R causes neuroserpin accumulation in neurons and is associated with progressive myoclonus epilepsy. J Neuropathol Exp Neurol (2000) 1.08
2,4-Dinitrophenyl receptors on mouse thymus and spleen cells. J Exp Med (1973) 1.07
Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors. Lab Invest (1999) 1.07
Demographic characteristics and opportunistic diseases associated with attrition during preparation for antiretroviral therapy in primary health centres in Kibera, Kenya. Trop Med Int Health (2011) 1.07
Stimulation of murine lymphocyte responses by cations. Cell Immunol (1986) 1.06
Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates. Arthritis Rheum (1995) 1.06
Acidic cellular environments: activation of latent TGF-beta and sensitization of cellular responses to TGF-beta and EGF. Int J Cancer (1989) 1.05
Antiretroviral therapy for HIV prevention: many concerns and challenges, but are there ways forward in sub-Saharan Africa? Trans R Soc Trop Med Hyg (2010) 1.05
Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center. J Biol Chem (1992) 1.05
Inactivation of plasminogen activator inhibitor by oxidants. Biochemistry (1986) 1.04
Identification and activation of latent transforming growth factor beta. Methods Enzymol (1991) 1.04
Susceptibility of C5-deficient mice to listeriosis: modulation by Concanavalin A. Cell Immunol (1978) 1.04
Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1. Circulation (2001) 1.04
Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer (2000) 1.03
Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab (1980) 1.03
Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family. Contribution of a covalent interaction to the binding energy of serpin-proteinase complexes. J Biol Chem (1995) 1.02
Transcriptional inhibition of the inducible nitric oxide synthase gene by competitive binding of NF-kappa B/Rel proteins. Biochem Biophys Res Commun (1995) 1.02
Regulation of the methionine feedback-sensitive enzyme in mutants of Salmonella typhimurium. J Bacteriol (1972) 1.01
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol (2012) 0.99
Alteration of transforming growth factor-beta1 response involves down-regulation of Smad3 signaling in myofibroblasts from skin fibrosis. Am J Pathol (2001) 0.99
In vivo footprinting of the mouse inducible nitric oxide synthase gene: inducible protein occupation of numerous sites including Oct and NF-IL6. Nucleic Acids Res (1996) 0.98
Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res (1999) 0.98
The serpin-proteinase complex revealed. Nat Struct Biol (1997) 0.96
Modulation of human colon tumor-stromal interactions by the endothelin system. Am J Pathol (2000) 0.96
[Metastatic renal cell carcinoma to the thyroid gland: report of seven cases and review of the literature]. Ann Chir (2004) 0.96
Rat macrophage-mediated toxicity to cancer cells; effect of endotoxins and endotoxin inhibitors contained in culture media. Eur J Immunol (1978) 0.95
Concurrent lymphoma and metastatic breast carcinoma in the axillary, confounding sentinel lymph-node biopsy. Eur J Surg Oncol (2004) 0.94
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma. Br J Cancer (2009) 0.94
Measurement of macrophage adherence and spreading with weak electric fields. J Immunol Methods (1990) 0.94
Level of methionyl-tRNA synthetase in merodiploids of Escherichia coli K12. Eur J Biochem (1970) 0.94
In vivo the environmental pollutants lead and mercury induce oligoclonal T cell responses skewed toward type-2 reactivities. Cell Immunol (1997) 0.94
Transforming growth factor-beta1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line. Int J Cancer (1997) 0.94
A histological comparison of adenomatous and hyperplastic parathyroid glands. J Clin Pathol (1978) 0.93
Serpin conformational change in ovalbumin. Enhanced reactive center loop insertion through hinge region mutations. Biochemistry (1997) 0.93
Cells transformed by Rous sarcoma virus release transforming growth factors. J Cell Physiol (1982) 0.93
New Zealand mixed mice: a genetic systemic lupus erythematosus model for assessing environmental effects. Environ Health Perspect (1999) 0.92
Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. J Thromb Haemost (2010) 0.92
Metal-induced modulation of nitric oxide production in vitro by murine macrophages: lead, nickel, and cobalt utilize different mechanisms. Toxicol Appl Pharmacol (1996) 0.92
Heat shock enhances transcriptional activation of the murine-inducible nitric oxide synthase gene. FASEB J (2000) 0.91
Lead potentiates cytokine- and glutamate-mediated increases in permeability of the blood-brain barrier. Neurotoxicology (1998) 0.91
Differential in vitro effects of physiological and atmospheric oxygen tension on normal human peripheral blood mononuclear cell proliferation, cytokine and immunoglobulin production. Int J Immunopharmacol (1996) 0.91
Differential effects of concanavalin A and phytohemagglutinin on murine immunity. Suppression and enhancement of humoral immunity. Cell Immunol (1977) 0.91
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. Ann Oncol (2012) 0.90
Sarcoidosis associated with Crohn's disease of ileum, mouth and oesophagus. J R Soc Med (1983) 0.89
Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thromb Res (2012) 0.89
Modulation of T-cell functions. I. Effect of 2-mercaptoethanol and macrophages on T-cell proliferation. Cell Immunol (1980) 0.89